ERBB2 and non-small cell lung carcinoma: Structurally similar to osimertinib, it possesses an enhanced inhibitory effect against EGFR exon 20 insertion and other non-sensitive mutations, as well as some inhibitory effect against lung cancer with HER2 exon 20 insertion mutations.150,151 In September 2021, the FDA approved mobocertinib for metastatic NSCLC, advanced NSCLC with EGFR mutation, locally advanced NSCLC, and advanced NSCLC.